Dossier assessment
Nintedanib (interstitial lung disease) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Nintedanib (interstitial lung disease) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Nintedanib (interstitial lung disease) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
| Adults with chronic progressive fibrosing interstitial lung diseases other than SSc-ILD or IPF |
Result of dossier assessment:
| The advantage in the outcome category of morbidity is accompanied by disadvantages in side effects; indication of minor added benefit |
Additional information
Federal Joint Committee (G-BA)
2021-02-04: A G-BA decision was published.
Project details
- Project no.
- A20-71
- Commission
- Commission awarded on 12.08.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
Connected Projects
-
Dossier assessment
Nintedanib (idiopathic pulmonary fibrosis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nintedanib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Nintedanib - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Addendum
Nintedanib (interstitial lung disease) - Addendum to Commission A20-71
Status: Commission completed
-
Dossier assessment
Nintedanib (systemic sclerosis associated interstitial lung disease in adults) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nintedanib (fibrosing interstitial lung diseases, 6 to < 18 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nintedanib (systemic sclerosis associated interstitial lung disease, 6 to < 18 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed